SEC Form 3 · accession 0001104659-18-057857
Y-mAbs Therapeutics, Inc. · YMAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Gad
Officer — President and Chairman · Director
Period of report
Sep 20, 2018
Accepted (ET)
Sep 20, 2018 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001722964
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,190,000 | I | By GAD Enterprises, LLC | |
| Common StockF2 | holding | — | — | — | 1,030,557 | I | By WG Biotech ApS |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $2.00 | holding | — | — | — | — | Jun 10, 2025 | Common Stock | 500,000 | — | D |
| Employee Stock Option (right to buy)F4 | $4.38 | holding | — | — | — | — | Oct 21, 2026 | Common Stock | 166,000 | — | D |
| Employee Stock Option (right to buy)F5 | $8.50 | holding | — | — | — | — | Dec 14, 2026 | Common Stock | 16,000 | — | D |
| Employee Stock Option (right to buy)F6 | $11.16 | holding | — | — | — | — | Apr 24, 2028 | Common Stock | 100,000 | — | D |
Explanation of responses
- F1Reporting Person is sole member and manager of GAD Enterprises, LLC and as such Reporting Person has sole voting and dispositive power with respect to such shares.
- F2WG Biotech ApS owns 5,010,000 shares of the Company's common stock. GAD Enterprises, LLC (of which Reporting Person is sole member and manager) owns 20.57% of WG Biotech ApS but has no voting or dispositive power over the shares of common stock held by WG Biotech ApS.
- F3The stock option vested and became exercisable as to 25% of the shares subject to the option on June 10, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F4The stock option vested and became exercisable as to 25% of the shares subject to the option on October 21, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F5The stock option vested and became exercisable as to 25% of the shares subject to the option on December 14, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F6The stock option shall vest and become exercisable as to 25% of the shares subject to the option on April 24, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.